Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence-Reference-Cited by-同舟云学术

Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence

Published:2022-11 Issue:11 Volume:34 Page:
ISSN:0953-8194
Container-title:Journal of Neuroendocrinology
language:en
Short-container-title:J Neuroendocrinology

Author:

Navalkissoor Shaunak¹^ORCID,Gnanasegaran Gopinath¹,Grossman Ashley²^ORCID

Affiliation:

1. Department of Nuclear Medicine, ENETS Centre of Excellence Royal Free London NHS Foundation Trust London UK

2. NET Unit, ENETS Centre of Excellence Royal Free London NHS Foundation Trust London UK

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Endocrine and Autonomic Systems,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jne.13208

Reference63 articles.

1. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

2. Summary of Product Characteristics of Lutathera[Internet].ec.europa.eu. Available from:https://ec.europa.eu/health/documents/community-register/2017/20170926138665/anx_138665_en.pdf. Accessed July 1 2022.

3. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

4. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

5. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient;The Journal of Clinical Endocrinology & Metabolism;2024-04-23

2. The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives;Endocrine Reviews;2024-02-20

3. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives;EJNMMI Radiopharmacy and Chemistry;2024-02-06